181 related articles for article (PubMed ID: 37265703)
21. Hypercalcemia of Malignancy Attributed to Cosecretion of PTH and PTHRP in Lung Adenocarcinoma.
Kroopnick JM; Martinez-Outschoorn U; Tuluc M; Kim CS
AACE Clin Case Rep; 2021; 7(3):200-203. PubMed ID: 34095488
[TBL] [Abstract][Full Text] [Related]
22. Mechanisms and treatment of hypercalcemia of malignancy.
Clines GA
Curr Opin Endocrinol Diabetes Obes; 2011 Dec; 18(6):339-46. PubMed ID: 21897221
[TBL] [Abstract][Full Text] [Related]
23. Conventional treatment of hypercalcemia of malignancy.
Davidson TG
Am J Health Syst Pharm; 2001 Nov; 58 Suppl 3():S8-15. PubMed ID: 11757206
[TBL] [Abstract][Full Text] [Related]
24. Cancer-induced hypercalcemia.
Lumachi F; Brunello A; Roma A; Basso U
Anticancer Res; 2009 May; 29(5):1551-5. PubMed ID: 19443365
[TBL] [Abstract][Full Text] [Related]
25. [Hypercalcemia of malignancy: clinical features, diagnosis and treatment].
Farias ML
Arq Bras Endocrinol Metabol; 2005 Oct; 49(5):816-24. PubMed ID: 16444366
[TBL] [Abstract][Full Text] [Related]
26. Parathyroid hormone and parathyroid hormone related protein assays in the investigation of hypercalcemic patients in hospital in a Chinese population.
Lee JK; Chuang MJ; Lu CC; Hao LJ; Yang CY; Han TM; Lam HC
J Endocrinol Invest; 1997; 20(7):404-9. PubMed ID: 9309539
[TBL] [Abstract][Full Text] [Related]
27. Passive immunization with anti-parathyroid hormone-related protein monoclonal antibody markedly prolongs survival time of hypercalcemic nude mice bearing transplanted human PTHrP-producing tumors.
Sato K; Yamakawa Y; Shizume K; Satoh T; Nohtomi K; Demura H; Akatsu T; Nagata N; Kasahara T; Ohkawa H
J Bone Miner Res; 1993 Jul; 8(7):849-60. PubMed ID: 8352067
[TBL] [Abstract][Full Text] [Related]
28. [Medical treatment of malignant hypercalcemia].
Eto S; Nakano Y; Okada Y
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2311-8. PubMed ID: 8259844
[TBL] [Abstract][Full Text] [Related]
29. Hypercalcemia of Malignancy in Thymic Carcinoma: Evolving Mechanisms of Hypercalcemia and Targeted Therapies.
Cheng C; Kuzhively J; Baim S
Case Rep Endocrinol; 2017; 2017():2608392. PubMed ID: 28168064
[TBL] [Abstract][Full Text] [Related]
30. [Treatment of malignancy associated hypercalcemia].
Tai N; Inoue D
Clin Calcium; 2014 Aug; 24(8):1223-8. PubMed ID: 25065875
[TBL] [Abstract][Full Text] [Related]
31. Current management strategies for hypercalcemia.
Pecherstorfer M; Brenner K; Zojer N
Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
[TBL] [Abstract][Full Text] [Related]
32. Hypercalcemia: A Review.
Walker MD; Shane E
JAMA; 2022 Oct; 328(16):1624-1636. PubMed ID: 36282253
[TBL] [Abstract][Full Text] [Related]
33. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
[TBL] [Abstract][Full Text] [Related]
34. Levels of parathyroid hormone-related protein (PTHrP) in hypercalcemia of malignancy are not lowered by treatment with the bisphosphonate BM 21.0955.
Blind E; Raue F; Meinel T; Wüster C; Ziegler R
Horm Metab Res; 1993 Jan; 25(1):40-4. PubMed ID: 8428711
[TBL] [Abstract][Full Text] [Related]
35. [Bone and calcium metabolism associated with malignancy. Malignancy-associated hypercalcemia.].
Tai N; Inoue D
Clin Calcium; 2018; 28(11):1503-1508. PubMed ID: 30374007
[TBL] [Abstract][Full Text] [Related]
36. Hypercalcemia of malignancy: pathophysiology, diagnosis and treatment.
Mosekilde L; Eriksen EF; Charles P
Crit Rev Oncol Hematol; 1991; 11(1):1-27. PubMed ID: 1883526
[TBL] [Abstract][Full Text] [Related]
37. The management of hypercalcemia of malignancy.
Harvey HA
Support Care Cancer; 1995 Mar; 3(2):123-9. PubMed ID: 7773580
[TBL] [Abstract][Full Text] [Related]
38. Hypercalcemia in the Intensive Care Unit: A Review of Pathophysiology, Diagnosis, and Modern Therapy.
Maier JD; Levine SN
J Intensive Care Med; 2015 Jul; 30(5):235-52. PubMed ID: 24130250
[TBL] [Abstract][Full Text] [Related]
39. Denosumab is Effective for Controlling Serum Calcium Levels in Patients with Humoral Hypercalcemia of Malignancy Syndrome: A Case Report on Parathyroid Hormone-related Protein-producing Cholangiocarcinoma.
Ashihara N; Nakajima K; Nakamura Y; Kobayashi M; Shirahata K; Maeda C; Uehara T; Gomi D; Ito N
Intern Med; 2016; 55(23):3453-3457. PubMed ID: 27904108
[TBL] [Abstract][Full Text] [Related]
40. Treatment of hypercalcemia of malignancy with bisphosphonates.
Berenson JR
Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]